Home » Medical » Surmodics’ Regulatory Win Marks a Positive Shift in Paclitaxel ControversyMedicalSurmodics’ Regulatory Win Marks a Positive Shift in Paclitaxel Controversy Manny Johnson June 13, 2020 3 Views Earlier this year the fate of Surmodics’ SurVeil CE mark submission was unclear as European regulators temporarily halted review of new paclitaxel devices. The tide has apparently turned, however, because the drug-coated balloon is now CE marked.
